Biotech Values

[DewDiligence]

Re: Swine flu / BAX

JPM analyst Mike Weinstein sez WHO Level 6 #swine flu is "a big deal" for vaccine maker BAX. Tells clients it could add 6-8 cents to EPS.

BAX is one of the “real” biotech companies that stands to benefit from the flu pandemic. I’m not sure that flu-related stuff will add 6-8 cents to BAX’s EPS, but every little bit helps.

In any case, BAX is a fine biotech company that’s trading at a reasonable valuation. This piece from Barron’s is a decent overview of the company’s business: #msg-35959663. The company’s Gammagard data in Alzheimer’s disease is described in #msg-31174404 and #msg-28594685. Regards, Dew